Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more
Tandem Diabetes Care Inc (TNDM) - Total Assets
Latest total assets as of December 2025: $881.11 Million USD
Based on the latest financial reports, Tandem Diabetes Care Inc (TNDM) holds total assets worth $881.11 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tandem Diabetes Care Inc - Total Assets Trend (2011–2025)
This chart illustrates how Tandem Diabetes Care Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tandem Diabetes Care Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tandem Diabetes Care Inc's total assets of $881.11 Million consist of 70.2% current assets and 29.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.3% |
| Accounts Receivable | $165.49 Million | 18.8% |
| Inventory | $128.77 Million | 14.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.72 Million | 1.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Tandem Diabetes Care Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tandem Diabetes Care Inc's current assets represent 70.2% of total assets in 2025, an increase from 70.0% in 2011.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2025, down from 61.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 18.8% of total assets.
Tandem Diabetes Care Inc Competitors by Total Assets
Key competitors of Tandem Diabetes Care Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Tandem Diabetes Care Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Tandem Diabetes Care Inc generates 1.15x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tandem Diabetes Care Inc is currently not profitable relative to its asset base.
Tandem Diabetes Care Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.55 | 2.93 | 6.40 |
| Quick Ratio | 2.02 | 2.33 | 5.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $375.42 Million | $ 477.44 Million | $ 558.29 Million |
Tandem Diabetes Care Inc - Advanced Valuation Insights
This section examines the relationship between Tandem Diabetes Care Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.31 |
| Latest Market Cap to Assets Ratio | 1.64 |
| Asset Growth Rate (YoY) | -8.9% |
| Total Assets | $881.11 Million |
| Market Capitalization | $1.44 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Tandem Diabetes Care Inc's assets above their book value (1.64 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Tandem Diabetes Care Inc's assets decreased by 8.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tandem Diabetes Care Inc (2011–2025)
The table below shows the annual total assets of Tandem Diabetes Care Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $881.11 Million | -8.94% |
| 2024-12-31 | $967.66 Million | +1.57% |
| 2023-12-31 | $952.66 Million | -9.51% |
| 2022-12-31 | $1.05 Billion | +16.31% |
| 2021-12-31 | $905.14 Million | +26.34% |
| 2020-12-31 | $716.41 Million | +119.69% |
| 2019-12-31 | $326.11 Million | +58.08% |
| 2018-12-31 | $206.29 Million | +116.36% |
| 2017-12-31 | $95.35 Million | -15.17% |
| 2016-12-31 | $112.39 Million | -10.17% |
| 2015-12-31 | $125.12 Million | +17.52% |
| 2014-12-31 | $106.46 Million | -34.37% |
| 2013-12-31 | $162.22 Million | +307.40% |
| 2012-12-31 | $39.82 Million | +184.86% |
| 2011-12-31 | $13.98 Million | -- |